Intravenous zanamivir was well-tolerated and associated with virologic response and clinical improvement in hospitalized children with influenza, according to the results of a study published in Pediatrics.

In this phase 2 open-label trial, 71 children hospitalized with influenza were enrolled to receive intravenous zanamivir (age- and weight-adjusted to provide a dose comparable to 600 mg twice-daily in adults) for 5 to 10 days. The primary outcomes were treatment-emergent adverse events, clinical laboratory measurements, and vital signs. Secondary outcomes included clinical outcomes, pharmacokinetics, and virologic efficacy data.

Treatment-emergent adverse events were reported in 72% of patients, and serious treatment-emergent adverse events occurred in 21% of patients. The mortality rate was 7%. Serious treatment-emergent adverse events and deaths were not considered to be related to zanamivir treatment.


Continue Reading

Pharmacokinetic analyses revealed that the mean zanamivir exposures in patients with normal renal function (n = 34) ranged from 64.5 to 110 hour·μg/mL.

After 2 days of treatment, viral load decreased by a median of 1.81 log10 copies/mL from baseline.

The study authors concluded that “the safety profile of [intravenous] zanamivir was consistent with that expected in children with severe influenza, with no newly identified drug-related adverse safety findings.”

Related Articles

Reference

Bradley J, Blumer JL, Romero JR, et al. Intravenous zanamivir in hospitalized patients with influenza. Pediatrics. 2017;140(5):e20162727.